Literature DB >> 25300749

The asymmetric syntheses of pyrrolizidines, indolizidines and quinolizidines via two sequential tandem ring-closure/N-debenzylation processes.

Stephen G Davies1, Ai M Fletcher, Emma M Foster, Ian T T Houlsby, Paul M Roberts, Thomas M Schofield, James E Thomson.   

Abstract

Concise asymmetric syntheses of (-)-lupinine, (+)-isoretronecanol, (+)-5-epi-tashiromine and (R,R)-1-(hydroxymethyl)octahydroindolizine (the azabicyclic core within stellettamides A-C) have been achieved in 8 steps or fewer from commercially available starting materials. The key steps in these syntheses involved the preparation of enantiopure β-amino esters, upon conjugate addition of lithium (R)-N-(p-methoxybenzyl)-N-(α-methyl-p-methoxybenzyl)amide to either ζ-chloro or ζ-hydroxy substituted tert-butyl (E)-hept-2-enoate, or ε-chloro or ε-hydroxy substituted tert-butyl (E)-hex-2-enoate. Activation of the ω-substituent as a leaving group led to SN2-type ring-closure, which occurred with concomitant N-debenzylation via an E1-type deprotection step, to give the corresponding pyrrolidine or piperidine in good yield. Subsequent alkylation of these enantiopure azacycles, followed by a second ring-closure/concomitant N-debenzylation step formed the pyrrolizidine, indolizidine or quinolizidine motif, and reduction with LiAlH4 gave the target compounds in diastereoisomerically and enantiomerically pure form.

Entities:  

Year:  2014        PMID: 25300749     DOI: 10.1039/c4ob01737d

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  2 in total

1.  Novel stereocontrolled syntheses of tashiromine and epitashiromine.

Authors:  Loránd Kiss; Enikő Forró; Ferenc Fülöp
Journal:  Beilstein J Org Chem       Date:  2015-04-30       Impact factor: 2.883

2.  New syntheses of (±)-tashiromine and (±)-epitashiromine via enaminone intermediates.

Authors:  Darren L Riley; Joseph P Michael; Charles B de Koning
Journal:  Beilstein J Org Chem       Date:  2016-12-02       Impact factor: 2.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.